Electronic health record data analysis on the impact of rescue-triggered inhaled corticosteroids on controller therapy in Black and Latinx individuals from a pragmatic, open-label, patient-level randomised trial.

Objective: The Person Empowered Asthma Relief (PREPARE) study found that as-needed inhaled corticosteroid (ICS) supplementation combined with participants' usual controller and rescue therapy reduced asthma exacerbations for Black and Hispanic/Latinx individuals. We aimed to determine whether treatment assignment to the intervention group (Patient Activated Reliever-Triggered ICS (PARTICS)) versus the control group (usual care) influenced controller therapy based on clinicians' written prescriptions.

Design: Secondary data analysis of electronic health record data of a pragmatic, open-label, patient-level randomised trial.

Myeloid activation clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer.

Patients with metastatic ovarian cancer (OvCa) have a 5-year survival rate of <30% due to the persisting dissemination of chemoresistant cells in the peritoneal fluid and the immunosuppressive microenvironment in the peritoneal cavity. Here, we report that intraperitoneal administration of β-glucan and IFNγ (BI) induced robust tumor regression in clinically relevant models of metastatic OvCa. BI induced tumor regression by controlling fluid tumor burden and activating localized antitumor immunity.

Clinician-Reported Barriers and Needs for Implementation of Continuous Glucose Monitoring.

Background: Continuous glucose monitoring (CGM) for patients with type 1 and type 2 diabetes is associated with improved clinical, behavioral, and psychosocial patient health outcomes and is part of the American Diabetes Association's Standards of Medical Care. CGM prescription often takes place in endocrinology practices, yet 50% of adults with type 1 diabetes and 90% of all people with type 2 diabetes receive their diabetes care in primary care settings. This study examined primary care clinicians' perceptions of barriers and resources needed to support CGM use in primary care.

Leveraging mixed-effects location scale models to assess the ERP mismatch negativity's psychometric properties and trial-by-trial neural variability in toddler-mother dyads.

Trial-by-trial neural variability, a measure of neural response stability, has been examined in relation to behavioral indicators using summary measures, but these methods do not characterize meaningful processes underlying variability. Mixed-effects location scale models (MELSMs) overcome these limitations by accounting for predictors and covariates of variability but have been rarely used in developmental studies. Here, we applied MELSMs to the ERP auditory mismatch negativity (MMN), a neural measure often related to language and psychopathology.